Case Study: Post-Traumatic Fibromyalgia Following Rear-End Collision

James Wong — Founder & Pharmacist, LienScripts | September 24, 2025 | 6 min read

A 38-year-old woman in Fresno was rear-ended and initially presented with what appeared to be routine soft tissue injuries. Three months later, her rheumatologist diagnosed fibromyalgia. The defense denied the diagnosis was accident-related — until the pharmacy record showed a clear before-and-after inflection point.

Case Study: Post-Traumatic Fibromyalgia Following Rear-End Collision

Details have been modified to protect patient privacy. This is a composite account based on real scenarios encountered in our practice.

Post-traumatic fibromyalgia is among the most contested diagnoses in personal injury law. The condition is real — recognized by the American College of Rheumatology, with validated diagnostic criteria, and supported by a substantial body of research on trauma as a precipitating factor. But its invisible nature, the delay between the precipitating injury and the diagnosis, and the subjectivity of some symptoms make it a common target for defense challenges.

In this case, the pharmacy record provided what no physician's note could fully convey: a before-and-after inflection point, documented in dates and drug names, that corroborated the treating rheumatologist's causation opinion.

[!KEY] Angela, 38, was rear-ended and appeared to have routine soft tissue injuries — three months later she was diagnosed with fibromyalgia, and the pharmacy record's abrupt shift from naproxen and cyclobenzaprine to FDA-approved fibromyalgia drugs made the causation argument virtually undeniable.

Patient Background

Angela was 38 years old, a dental hygienist in Fresno, when she was rear-ended at moderate speed — estimated 35 mph — by a distracted driver while stopped at a traffic light. The impact was significant enough to move her vehicle approximately ten feet forward and deploy the driver's side curtain airbag.

Initial emergency evaluation found no fractures and no acute neurological deficits. She was discharged with a diagnosis of cervical and lumbar strain and referred to her primary care physician for follow-up.

The first three months of treatment were clinically unremarkable. Her medications were:

• Naproxen — for inflammation and soft tissue pain
• Cyclobenzaprine — for muscle spasm
• Physical therapy — twice weekly for six weeks

These are the standard medications for cervical and lumbar strain. Angela was adherent, attended all her therapy sessions, and showed early progress in range of motion restoration. The case appeared to be heading toward a standard soft tissue resolution.

The Three-Month Inflection: Fibromyalgia Emerges

At approximately three months post-accident, Angela's clinical picture changed in a way that was difficult to explain by the original injury alone.

She developed:

• Widespread musculoskeletal pain — not localized to the cervical and lumbar regions of the initial injury, but diffuse, involving the shoulders, hips, upper arms, and thighs
• Severe fatigue — disproportionate to her level of activity, persisting through adequate sleep
• Cognitive difficulty — concentration problems, memory lapses, and processing slowdowns that she and her family described as "fibro fog"
• Sleep disruption — unrestorative sleep despite normal duration, with frequent nighttime awakening
• Mood changes — anxiety, emotional lability, and a persistent low-level depression

Her primary care physician referred her to a rheumatologist. At the rheumatology evaluation, Angela met the American College of Rheumatology 2010 Diagnostic Criteria for fibromyalgia: widespread pain index of 12 out of 19 body sites, symptom severity scale score of 10, symptoms present for more than three months.

The diagnosis: fibromyalgia, with the onset temporally consistent with the rear-end collision as the precipitating event.

Why Trauma Can Trigger Fibromyalgia

The relationship between physical trauma and fibromyalgia onset is supported by a meaningful body of research. Post-traumatic fibromyalgia — sometimes called "traumatically induced fibromyalgia" — typically presents within weeks to months of a precipitating event, most commonly motor vehicle accidents, surgical procedures, or significant physical stress.

The proposed mechanism involves central sensitization: trauma disrupts the normal central nervous system pain modulation pathways, causing the brain and spinal cord to amplify pain signals from all over the body rather than just from the injury site. Once central sensitization is established, it tends to persist even after the precipitating injury has healed.

For Angela, this meant that the cervical and lumbar strain — which would have been the entire injury in a different patient — was the triggering event for a syndrome that spread far beyond those structures.

[!KEY] Post-traumatic fibromyalgia cases require the prescribing physician to document both the absence of pre-accident fibromyalgia symptoms and the temporal connection to the collision — without that documentation, the defense will argue the diagnosis was pre-existing or coincidental, regardless of the pharmacy record.

The Medications: A Stark Before-and-After

Angela's treating rheumatologist prescribed the medications that are FDA-approved or widely accepted as first-line for fibromyalgia management:

Duloxetine (Cymbalta), 60mg daily — duloxetine is one of two medications with FDA approval specifically for fibromyalgia. It works as a serotonin-norepinephrine reuptake inhibitor and has demonstrated efficacy for the central sensitization pain, fatigue, and cognitive symptoms of fibromyalgia in large controlled trials.

Pregabalin (Lyrica), 150mg twice daily — pregabalin is the second FDA-approved medication specifically for fibromyalgia. It modulates the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the hyperexcitability of central pain pathways that drives fibromyalgia symptoms.

Amitriptyline, 25mg at bedtime — a tricyclic antidepressant used in low doses specifically for fibromyalgia-related sleep disruption. At this dose, it is not functioning primarily as an antidepressant — it is improving sleep architecture, which is chronically disrupted in fibromyalgia and which, when improved, often reduces daytime pain intensity.

Hydroxyzine, as needed — for anxiety and sleep support on breakthrough nights.

These four medications represent a clinically coherent fibromyalgia regimen. What made them evidentiary was their specificity: duloxetine and pregabalin are prescribed almost exclusively for fibromyalgia, neuropathic pain, or generalized anxiety disorder. Amitriptyline at 25mg at bedtime is a recognized fibromyalgia sleep intervention. None of these were prescribed for the original soft tissue injury.

The Defense Challenge — and the Pharmacy Record's Response

The defense insurer raised two challenges to the fibromyalgia claim:

First: that the fibromyalgia diagnosis was unrelated to the accident — that it was a pre-existing condition that happened to become symptomatic around the same time.

Second: that even if the accident had triggered fibromyalgia, the damages were overstated because the patient's original soft tissue injuries were minor.

Angela's attorney anticipated both. The medical record addressed the causation question — her rheumatologist had documented a full review of systems prior to the accident, finding no prior fibromyalgia symptoms, and had specifically recorded the temporal relationship between the collision and the symptom onset.

But the pharmacy record addressed it differently, and perhaps more powerfully.

The pharmacy record showed two distinct medication phases:

Months 1–3: Naproxen, cyclobenzaprine. Standard soft tissue injury medications. Nothing unusual.

Month 3 onward: Duloxetine, pregabalin, amitriptyline, hydroxyzine. A completely different medication set — medications that are not prescribed for soft tissue strain, that are prescribed specifically for fibromyalgia and its consequences.

The inflection was visible in the record without any clinical annotation. The date of the first duloxetine fill — which matched the date of the rheumatology diagnosis to within two days — was the point at which the case transformed from a soft tissue injury into a fibromyalgia case.

"The pharmacy record's before-and-after inflection point — standard soft tissue drugs through month three, then FDA-approved fibromyalgia medications — was visible without any annotation, and no defense expert could explain it away." No one could argue that Angela had taken these medications before the accident, because the pharmacy record started on the date she began care through the lien, and it showed nothing in those categories in the months before the diagnosis.

The Access Challenge: Why the Lien Was Needed

Angela's health insurance covered her primary care visits and the initial medications. When the fibromyalgia diagnosis was made, however, the insurer balked at the new prescriptions. Duloxetine at 60mg and pregabalin at a therapeutic fibromyalgia dose both required prior authorizations. The insurer's formulary required step therapy — she had to fail cheaper generic alternatives first.

The step therapy requirements would have delayed therapeutic access by weeks and required her to take medications that her rheumatologist had not selected as first-line for her specific presentation. Her attorney enrolled her in a LienScripts pharmacy lien.

Under the lien, Angela received her prescribed medications — duloxetine, pregabalin, amitriptyline, and hydroxyzine — at zero upfront cost, without step therapy requirements, from the date of the rheumatology visit. The lien maintained that coverage for the duration of the litigation.

Outcome

The case resolved for a significantly higher amount than the initial demand from the defense insurer. The defense had opened with an offer consistent with a standard soft tissue injury settlement. Angela's attorney responded with the pharmacy record — showing the clear inflection from naproxen and cyclobenzaprine to duloxetine, pregabalin, and amitriptyline — alongside the rheumatologist's causation opinion and the diagnostic documentation.

Faced with FDA-approved fibromyalgia medications that had no explanation other than the diagnosis, and a diagnosis that had no documented history prior to the accident, the defense's causation argument became difficult to sustain.

Key Takeaways for Attorneys

1. Post-traumatic fibromyalgia cases are won and lost on causation documentation. The rheumatologist's clinical opinion establishes causation. The pharmacy record corroborates it — by showing the exact moment the medication regimen transformed from soft tissue injury management to fibromyalgia management.

[!TIP] In post-traumatic fibromyalgia cases, present the pharmacy record's inflection point alongside the rheumatologist's causation opinion — the dated shift from standard soft tissue drugs to FDA-approved fibromyalgia agents provides objective corroboration no defense expert can credibly dismiss.

2. FDA-approved fibromyalgia medications are uniquely probative. Duloxetine and pregabalin have specific FDA indications for fibromyalgia. When a patient is prescribed both, simultaneously, for the first time, within days of a fibromyalgia diagnosis — that is not coincidence. It is documented, dated corroboration of the diagnosis and its onset.

[!KEY] Insurance step therapy requirements would have forced the patient onto formulary substitutes rather than the drugs the rheumatologist actually chose — a pharmacy lien bypasses step therapy entirely, so the record reflects the treating physician's clinical judgment, not the insurer's formulary workaround.

3. The lien protects the medication record's integrity by eliminating step therapy delays. When insurance step therapy requirements would delay or alter the prescribed medications, the pharmacy lien ensures the patient receives exactly what was clinically chosen — which means the pharmacy record reflects the treating physician's actual clinical judgment, not the insurer's formulary workarounds.

Key Takeaways for Patients

1. If your symptoms spread beyond your original injury site, tell your doctor. Fibromyalgia developing after trauma often goes undiagnosed for months because patients assume the new, widespread symptoms are just a continuation of the original injury. If your pain is spreading, your fatigue is severe, or you are experiencing cognitive difficulties, request a rheumatology referral.

2. Your before-and-after medication history is clinical evidence. The change in your prescriptions at the time of a fibromyalgia diagnosis — from routine pain medications to FDA-approved fibromyalgia agents — is documented in your pharmacy record. That documentation supports your case in a way that self-reported symptoms alone cannot.

3. Step therapy requirements should not override your rheumatologist's judgment. If your insurer requires you to try cheaper alternatives before covering the medications your specialist prescribed, your attorney can explore pharmacy lien coverage. You should receive the medications your treating physician chose, not the ones your insurer's formulary prefers.

Related Resources

• Fibromyalgia After an Accident — Pharmacy Lien Guide
• Duloxetine for Chronic Pain After an Accident
• Pregabalin for Nerve Damage After a Car Accident
• Insurance Denial and Medication Access
• For Attorneys: How LienScripts Works
• Pharmacy Services for Personal Injury Clients: How It Works